Compare KraneShares Electric Vehicles and Future Mobility (KARS) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares Electric Vehicles and Future Mobility vs Sana Biotechnology Inc — how do they compare? KraneShares Electric Vehicles and Future Mobility trades at $29.85, while Sana Biotechnology Inc trades at $3.17 (market cap $873.84M). The key difference: KraneShares Electric Vehicles and Future Mobility is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| KARS | SANA | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $38.01 | $5.92 |
52-Week Low | $23.61 | $2.68 |
Market Cap | — | $873.84M |
Enterprise Value | — | $848.03M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KARS trades at $29.15, down 0.98% with bearish technical signals across moving averages and oscillators. The stock shows oversold conditions with RSI at 27.23, while facing resistance at $30. Recent industry news highlights strong global EV sales growth and China's expanding market presence, though US adoption lags behind international markets.
The EV sector faces competitive pressures from Chinese manufacturers and regulatory uncertainty, while benefiting from rising fuel prices driving consumer demand. KARS's performance depends on broader industry trends rather than company-specific fundamentals, with technical indicators suggesting continued near-term pressure.
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
